Global Wormer Testing Rules Now Include Pigs Too
Published Date: 6/24/2026
Notice
Summary
The FDA just released new guidance to help vets and drug makers test worm-killing medicines for pigs. This makes it easier to get these medicines approved worldwide by using the same testing rules. If you work with pig medicines, start following these recommendations now to save time and money on approvals.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Porcine Anthelmintic Study Guidelines
The FDA published final Guidance for Industry (GFI #110) on June 24, 2026 that gives study-design recommendations for testing worm‑killing (anthelmintic) drugs for pigs. The guidance is meant to help regulators in the United States, the European Union, and Japan accept the same effectiveness data so manufacturers can meet national or regional approval requirements.
Guidance Is Non‑Binding Flexibility
The FDA states this guidance does not establish any rights and is not binding. You may use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-12682, International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Equines; Guidance for Industry; Availability
The FDA just released new guidance to help companies test worm-killing medicines for horses. This makes it easier for drug makers worldwide to prove their products work, speeding up approvals and keeping horses healthy. If you’re in the veterinary or animal medicine world, this update is your new go-to starting June 24, 2026.
Next: 2026-12684, International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Canines; Guidance for Industry; Availability
The FDA just released new guidance to help companies test worm-killing medicines for dogs. This makes it easier for drug makers worldwide to prove their products work, speeding up approvals and keeping pups healthier. If you’re in the veterinary medicine business, this update could save time and money starting now!